1. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. *Neurology* 2008;70:779–787.
2. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. *Clin Cancer Res* 2007;13:1253–1259.
3. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. *Neurology* 2006;66:1258–1260.
4. Prados MD, Lamborn K, Yung WKA, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a NABTC study. *Neuro-Oncology* 2006;8:189–193.
5. Batchelor TT, Sorensen AG, diTomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell* 2007;11:83–95.
6. Stark-Vance V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma. *Neuro-Oncology* 2005;7:369.
7. Li JL, Sainson RC, Shi W, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. *Cancer Res* 2007;67:11244–11253.
8. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 1990;8:1277–1280.
9. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. *Exp Rev Anticancer Ther* 2007;7:1537–1560.

CORRECTION

A case of ALS-FTD in a large FALS pedigree with a K17I *ANG* mutation

In the Clinical/Scientific Note “A case of ALS-FTD in a large FALS pedigree with a K17I *ANG* mutation” by M.A. van Es et al. (*Neurology*® 2009;72:287–288), K17I was incorrectly labeled as K171 in panels A and B of the figure. The editorial staff regrets the error.

Neurology[®]

A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation

Neurology 2009;72;774

DOI 10.1212/01.wnl.0000344282.98635.2d

This information is current as of February 23, 2009

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/72/8/774.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.